“Improved Survival After Transplantation Of More Donor Plasmacytoid Dendritic Or Naïve T Cells From Unrelated-Donor Marrow Grafts: Results From Bmtctn 0201.”. J Clin Oncol 32 (22). J Clin Oncol: 2365-72. doi:10.1200/JCO.2013.54.4577.
. 2014. “Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation For Acute Myeloid Leukemia And Myelodysplastic Syndromes.”. J Clin Oncol 35 (11). J Clin Oncol: 1154-1161. doi:10.1200/JCO.2016.70.7091.
. 2017. “Peripheral-Blood Stem Cells Versus Bone Marrow From Unrelated Donors.”. N Engl J Med 367 (16). N Engl J Med: 1487-96. doi:10.1056/NEJMoa1203517.
. 2012. “Three Prophylaxis Regimens (Tacrolimus, Mycophenolate Mofetil, And Cyclophosphamide; Tacrolimus, Methotrexate, And Bortezomib; Or Tacrolimus, Methotrexate, And Maraviroc) Versus Tacrolimus And Methotrexate For Prevention Of Graft-Versus-Host Disease With”. Lancet Haematol 6 (3). Lancet Haematol: e132-e143. doi:10.1016/S2352-3026(18)30221-7.
. 2019.